The stock of TG Therapeutics Inc (NASDAQ:TGTX) is a huge mover today! About 207,066 shares traded hands. TG Therapeutics Inc (NASDAQ:TGTX) has declined 45.24% since April 4, 2016 and is downtrending. It has underperformed by 46.33% the S&P500.
The move comes after 9 months positive chart setup for the $297.83 million company. It was reported on Nov, 4 by Barchart.com. We have $13.68 PT which if reached, will make NASDAQ:TGTX worth $482.48M more.
Analysts await TG Therapeutics Inc (NASDAQ:TGTX) to report earnings on November, 14. They expect $-0.32 EPS, down 14.29% or $0.04 from last year’s $-0.28 per share. After $-0.33 actual EPS reported by TG Therapeutics Inc for the previous quarter, Wall Street now forecasts -3.03% EPS growth.
TG Therapeutics Inc (NASDAQ:TGTX) Ratings Coverage
Out of 6 analysts covering TG Therapeutics (NASDAQ:TGTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TG Therapeutics has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The rating was reinitiated by H.C. Wainwright on Wednesday, August 12 with “Buy”. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Strong Buy” rating given on Wednesday, September 9 by Raymond James. Brean Capital reinitiated the stock with “Buy” rating in Thursday, October 6 report. Suntrust Robinson initiated it with “Buy” rating and $18 target price in Friday, May 27 report. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Buy” rating by SunTrust on Friday, May 27. The company was initiated on Tuesday, December 1 by FBR Capital. The rating was upgraded by Zacks to “Hold” on Wednesday, August 12.
According to Zacks Investment Research, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 0.09, from 1.45 in 2016Q1. The ratio increased, as 10 funds sold all TG Therapeutics Inc shares owned while 18 reduced positions. 14 funds bought stakes while 29 increased positions. They now own 29.49 million shares or 0.54% more from 29.33 million shares in 2016Q1.
Mariner Wealth Advsr Limited Company holds 19,086 shares or 0.01% of its portfolio. Secor L P, a New York-based fund reported 30,820 shares. Schwab Charles Management, a California-based fund reported 59,050 shares. Retail Bank Of America De reported 10,484 shares or 0% of all its holdings. Tiaa Cref Invest Limited Company reported 115,728 shares or 0% of all its holdings. Baldwin Brothers Ma last reported 15,850 shares in the company. Raymond James Associates accumulated 0% or 15,400 shares. Moreover, Guggenheim Cap Lc has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 164,213 shares. New York State Common Retirement Fund has 0% invested in the company for 223,851 shares. Geode Lc last reported 277,277 shares in the company. Opaleye Mgmt last reported 1.06% of its portfolio in the stock. Columbus Circle reported 577,769 shares or 0.04% of all its holdings. The United Kingdom-based Pictet Asset has invested 0.04% in TG Therapeutics Inc (NASDAQ:TGTX). California Employees Retirement holds 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 124,800 shares. Art Advsr Limited Liability owns 88,654 shares or 0.03% of their US portfolio.
Insider Transactions: Since July 5, 2016, the stock had 0 insider buys, and 1 sale for $302,052 net activity. 50,426 shares were sold by Power Sean A, worth $302,052 on Tuesday, July 5.
More recent TG Therapeutics Inc (NASDAQ:TGTX) news were published by: Globenewswire.com which released: “TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2016 Financial …” on November 03, 2016. Also Prnewswire.com published the news titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 19, 2016. Fool.com‘s news article titled: “Why TG Therapeutics, Inc. Stock Is Dropping Today” with publication date: October 13, 2016 was also an interesting one.
TGTX Company Profile
TG Therapeutics, Inc. (TG), incorporated on May 18, 1993, is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Firm is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Firm is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Firm also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Firm also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.